Cytogenetics in the management of mature T-cell and NK-cell neoplasms: Guidelines from the groupe francophone de cytogénétique hématologique (GFCH)

Alaggio, 2022, The 5th edition of the World Health Organization classification of Haematolymphoid tumours: lymphoid Neoplasms, Leukemia, 36, 1720, 10.1038/s41375-022-01620-2 Nelson, 2008, Cytogenetic abnormalities and clinical correlations in peripheral T-cell lymphoma, Br J Haematol, 141, 461, 10.1111/j.1365-2141.2008.07042.x Bossi, 2020, Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy, Am J Hematol, 95, E319, 10.1002/ajh.25967 Tsuyama, 2017, Anaplastic large cell lymphoma: pathology, genetics, and clinical aspects, J Clin Exp Hematop, 57, 120, 10.3960/jslrt.17023 Salaverria, 2008, Genomic profiling reveals different genetic aberrations in systemic ALK-positive and ALK-negative anaplastic large cell lymphomas, Br J Haematol, 140, 516, 10.1111/j.1365-2141.2007.06924.x Falini, 1999, Lymphomas expressing ALK fusion protein(s) other than NPM-ALK, Blood, 94, 3509 Boi, 2013, PRDM1/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma, Blood, 122, 2683, 10.1182/blood-2013-04-497933 Parrilla Castellar, 2014, ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes, Blood, 124, 1473, 10.1182/blood-2014-04-571091 Hapgood, 2019, Identification of high-risk DUSP22-rearranged ALK-negative anaplastic large cell lymphoma, Br J Haematol, 186, e28, 10.1111/bjh.15860 Feldman, 2011, Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing, Blood, 117, 915, 10.1182/blood-2010-08-303305 King, 2016, Morphologic Features of ALK-negative Anaplastic Large Cell Lymphomas With DUSP22 Rearrangements, Am J Surg Pathol, 40, 36, 10.1097/PAS.0000000000000500 Pedersen, 2017, DUSP22 and TP63 rearrangements predict outcome of ALK-negative anaplastic large cell lymphoma: a Danish cohort study, Blood, 130, 554, 10.1182/blood-2016-12-755496 Sibon, 2023, ALK-negative anaplastic large cell lymphoma with DUSP22 rearrangement has distinctive disease characteristics with better progression-free survival: a LYSA study, Haematologica, 108, 1590, 10.3324/haematol.2022.281442 Qiu, 2023, DUSP22 rearrangement is associated with a distinctive immunophenotype but not outcome in patients with systemic ALK-negative anaplastic large cell lymphoma, Haematologica, 108, 1604, 10.3324/haematol.2022.281222 Campo, 2022, The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee, Blood, 140, 1229, 10.1182/blood.2022015851 Vasmatzis, 2012, Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas, Blood, 120, 2280, 10.1182/blood-2012-03-419937 Karube, 2020, Double-hit” of DUSP22 and TP63 rearrangements in anaplastic large cell lymphoma, ALK-negative, Blood, 135, 700, 10.1182/blood.2019004164 Crescenzo, 2015, Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma, Cancer Cell, 27, 516, 10.1016/j.ccell.2015.03.006 Luchtel, 2019, Recurrent MSC E116K mutations in ALK-negative anaplastic large cell lymphoma, Blood, 133, 2776, 10.1182/blood.2019000626 Quesada, 2019, Breast implant-associated anaplastic large cell lymphoma: a review, Mod Pathol, 32, 166, 10.1038/s41379-018-0134-3 Los-de Vries, 2020, Chromosome 20 loss is characteristic of breast implant-associated anaplastic large cell lymphoma, Blood, 136, 2927, 10.1182/blood.2020005372 Quesada, 2021, Next generation sequencing of breast implant-associated anaplastic large cell lymphomas reveals a novel STAT3-JAK2 fusion among other activating genetic alterations within the JAK-STAT pathway, Breast J, 27, 314, 10.1111/tbj.14205 Streubel, 2006, Novel t(5;9)(q33;q22) fuses ITK to SYK in unspecified peripheral T-cell lymphoma, Leukemia, 20, 313, 10.1038/sj.leu.2404045 Drieux, 2021, Detection of gene fusion transcripts in peripheral T-cell lymphoma using a multiplexed targeted sequencing assay, J Mol Diagn, 23, 929, 10.1016/j.jmoldx.2021.04.013 Lachenal, 2007, Angioimmunoblastic T-cell lymphoma: clinical and laboratory features at diagnosis in 77 patients, Medicine (Baltimore), 86, 282, 10.1097/MD.0b013e3181573059 Yu, 2021, Update on recurrent mutations in angioimmunoblastic T-cell lymphoma, Int J Clin Exp Pathol, 14, 1108 Steinhilber, 2019, The pathological features of angioimmunoblastic T-cell lymphomas with IDH2(R172) mutations, Mod Pathol, 32, 1123, 10.1038/s41379-019-0254-4 Odejide, 2014, A targeted mutational landscape of angioimmunoblastic T-cell lymphoma, Blood, 123, 1293, 10.1182/blood-2013-10-531509 Sakata-Yanagimoto, 2014, Somatic RHOA mutation in angioimmunoblastic T cell lymphoma, Nat Genet, 46, 171, 10.1038/ng.2872 Ng, 2018, Epstein-Barr virus-associated primary nodal T/NK-cell lymphoma shows a distinct molecular signature and copy number changes, Haematologica, 103, 278, 10.3324/haematol.2017.180430 Amador, 2019, Reproducing the molecular subclassification of peripheral T-cell lymphoma-NOS by immunohistochemistry, Blood, 134, 2159, 10.1182/blood.2019000779 Heavican, 2019, Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma, Blood, 133, 1664, 10.1182/blood-2018-09-872549 Weiss, 2023, PTCL, NOS: an update on classification, risk-stratification, and treatment, Front Oncol, 13, 10.3389/fonc.2023.1101441 Staber, 2019, Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia, Blood, 134, 1132, 10.1182/blood.2019000402 Hu, 2017, Prognostic significance of cytogenetic abnormalities in T-cell prolymphocytic leukemia, Am J Hematol, 92, 441, 10.1002/ajh.24679 Jain, 2017, Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL), Ann Oncol, 28, 1554, 10.1093/annonc/mdx163 Matutes, 1991, Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia, Blood, 78, 3269, 10.1182/blood.V78.12.3269.3269 Braun, 2021, Advanced pathogenetic concepts in T-cell prolymphocytic leukemia and their translational impact, Front Oncol, 11, 10.3389/fonc.2021.775363 Torabi, 2023, T-cell prolymphocytic leukemia/lymphoma with TCRB::TCL1 translocation, Blood, 142, 119, 10.1182/blood.2023020401 Sun, 2018, Comparison of karyotyping, TCL1 fluorescence in situ hybridisation and TCL1 immunohistochemistry in T cell prolymphocytic leukaemia, J Clin Pathol, 71, 309, 10.1136/jclinpath-2017-204616 Narducci, 2000, Regulation of TCL1 expression in B- and T-cell lymphomas and reactive lymphoid tissues, Cancer Res, 60, 2095 Hu, 2023, T-Cell Prolymphocytic Leukemia With t(X;14)(q28;q11.2): a Clinicopathologic Study of 15 Cases, Am J Clin Pathol, 159, 325, 10.1093/ajcp/aqac166 De Schouwer, 2000, T-cell prolymphocytic leukaemia: antigen receptor gene rearrangement and a novel mode of MTCP1 B1 activation, Br J Haematol, 110, 831, 10.1046/j.1365-2141.2000.02256.x Schrader, 2018, Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL, Nat Commun, 9, 697, 10.1038/s41467-017-02688-6 Patil, 2020, Reconstruction of rearranged T-cell receptor loci by whole genome and transcriptome sequencing gives insights into the initial steps of T-cell prolymphocytic leukemia, Genes Chromosomes Cancer, 59, 261, 10.1002/gcc.22821 Maljaei, 1998, Abnormalities of chromosomes 8, 11, 14, and X in T-prolymphocytic leukemia studied by fluorescence in situ hybridization, Cancer Genet Cytogenet, 103, 110, 10.1016/S0165-4608(97)00410-X Braun, 2022, Noncanonical Function of AGO2 Augments T-cell Receptor Signaling in T-cell Prolymphocytic Leukemia, Cancer Res, 82, 1818, 10.1158/0008-5472.CAN-21-1908 Durig, 2007, Combined single nucleotide polymorphism-based genomic mapping and global gene expression profiling identifies novel chromosomal imbalances, mechanisms and candidate genes important in the pathogenesis of T-cell prolymphocytic leukemia with inv(14)(q11q32), Leukemia, 21, 2153, 10.1038/sj.leu.2404877 Nowak, 2009, Molecular allelokaryotyping of T-cell prolymphocytic leukemia cells with high density single nucleotide polymorphism arrays identifies novel common genomic lesions and acquired uniparental disomy, Haematologica, 94, 518, 10.3324/haematol.2008.001347 Le Toriellec, 2008, Haploinsufficiency of CDKN1B contributes to leukemogenesis in T-cell prolymphocytic leukemia, Blood, 111, 2321, 10.1182/blood-2007-06-095570 Wahnschaffe, 2019, JAK/STAT-Activating Genomic Alterations Are a Hallmark of T-PLL, Cancers (Basel), 11, 1833, 10.3390/cancers11121833 Lopez, 2016, Genes encoding members of the JAK-STAT pathway or epigenetic regulators are recurrently mutated in T-cell prolymphocytic leukaemia, Br J Haematol, 173, 265, 10.1111/bjh.13952 Johansson, 2018, SAMHD1 is recurrently mutated in T-cell prolymphocytic leukemia, Blood Cancer J, 8, 11, 10.1038/s41408-017-0036-5 Barila, 2020, Stat3 mutations impact on overall survival in large granular lymphocyte leukemia: a single-center experience of 205 patients, Leukemia, 34, 1116, 10.1038/s41375-019-0644-0 Rajala, 2013, Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia, Blood, 121, 4541, 10.1182/blood-2012-12-474577 Bhattacharya, 2022, Identification of novel STAT5B mutations and characterization of TCRbeta signatures in CD4+ T-cell large granular lymphocyte leukemia, Blood Cancer J, 12, 31, 10.1038/s41408-022-00630-8 Baer, 2022, CCL22 mutations drive natural killer cell lymphoproliferative disease by deregulating microenvironmental crosstalk, Nat Genet, 54, 637, 10.1038/s41588-022-01059-2 Yoshida, 2021, Clinical Applications of Genomic Alterations in ATLL: predictive Markers and Therapeutic Targets, Cancers (Basel), 13, 10.3390/cancers13081801 Sakamoto, 2021, Clinical significance of CD28 gene-related activating alterations in adult T-cell leukaemia/lymphoma, Br J Haematol, 192, 281, 10.1111/bjh.17211 Sun, 2019, Cytogenetic analysis of adult T-cell leukemia/lymphoma: evaluation of a Caribbean cohort, Leuk Lymphoma, 60, 1598, 10.1080/10428194.2018.1538506 Zhang, 2021, Karyotypic complexity, TP53 pathogenic variants, and increased number of variants on Next-Generation Sequencing are associated with disease progression in a North American adult T-cell leukemia/lymphoma cohort, Int J Lab Hematol, 43, 651, 10.1111/ijlh.13577 Kataoka, 2018, Prognostic relevance of integrated genetic profiling in adult T-cell leukemia/lymphoma, Blood, 131, 215, 10.1182/blood-2017-01-761874 Caprini, 2009, Identification of key regions and genes important in the pathogenesis of sezary syndrome by combining genomic and expression microarrays, Cancer Res, 69, 8438, 10.1158/0008-5472.CAN-09-2367 Laharanne, 2010, Genome-wide analysis of cutaneous T-cell lymphomas identifies three clinically relevant classes, J Invest Dermatol, 130, 1707, 10.1038/jid.2010.8 da Silva Almeida, 2015, The mutational landscape of cutaneous T cell lymphoma and Sézary syndrome, Nat Genet, 47, 1465, 10.1038/ng.3442 Kiel, 2015, Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK-STAT pathway in Sézary syndrome, Nat Commun, 6, 8470, 10.1038/ncomms9470 van Doorn, 2009, Oncogenomic analysis of mycosis fungoides reveals major differences with Sezary syndrome, Blood, 113, 127, 10.1182/blood-2008-04-153031 Salgado, 2010, Oligonucleotide array-CGH identifies genomic subgroups and prognostic markers for tumor stage mycosis fungoides, J Invest Dermatol, 130, 1126, 10.1038/jid.2009.306 Melchers, 2020, Clinical, histologic, and molecular characteristics of anaplastic lymphoma kinase-positive primary cutaneous anaplastic large cell lymphoma, Am J Surg Pathol, 44, 776, 10.1097/PAS.0000000000001449 Ortiz-Hidalgo, 2023, Primary Cutaneous Anaplastic Large Cell Lymphoma-A Review of Clinical, Morphological, Immunohistochemical, and Molecular Features, Cancers (Basel), 15, 4098, 10.3390/cancers15164098 Karai, 2013, Chromosomal rearrangements of 6p25.3 define a new subtype of lymphomatoid papulosis, Am J Surg Pathol, 37, 1173, 10.1097/PAS.0b013e318282d01e Velusamy, 2014, A novel recurrent NPM1-TYK2 gene fusion in cutaneous CD30-positive lymphoproliferative disorders, Blood, 124, 3768, 10.1182/blood-2014-07-588434 Bastidas Torres, 2022, Whole-genome profiling of primary cutaneous anaplastic large cell lymphoma, Haematologica, 107, 1619, 10.3324/haematol.2020.263251 Bojanini, 2021, Outcomes of Hepatosplenic T-Cell Lymphoma: the Mayo Clinic Experience, Clin Lymphoma Myeloma Leuk, 21, 10.1016/j.clml.2020.09.013 Pro, 2020, Hepatosplenic T-cell lymphoma: a rare but challenging entity, Blood, 136, 2018, 10.1182/blood.2019004118 Weidmann, 2000, Hepatosplenic T cell lymphoma. A review on 45 cases since the first report describing the disease as a distinct lymphoma entity in 1990, Leukemia, 14, 991, 10.1038/sj.leu.2401784 Jain, 2018, A rare case of hepatosplenic gammadelta T-cell lymphoma expressing CD19 with ring chromosome 7 and trisomy 8, Cancer Genet, 228–229, 17, 10.1016/j.cancergen.2018.06.003 Finalet Ferreiro, 2014, Integrative genomic and transcriptomic analysis identified candidate genes implicated in the pathogenesis of hepatosplenic T-cell lymphoma, PLoS ONE, 9, 10.1371/journal.pone.0102977 McKinney, 2017, The genetic basis of hepatosplenic T-cell lymphoma, Cancer Discov, 7, 369, 10.1158/2159-8290.CD-16-0330 Yabe, 2017, Distinguishing between hepatosplenic T-cell lymphoma and γδ T-cell large granular lymphocytic leukemia: a clinicopathologic, immunophenotypic, and molecular analysis, Am J Surg Pathol, 41, 82, 10.1097/PAS.0000000000000743 Gorodetskiy, 2021, The non-leukemic T cell large granular lymphocytic leukemia variant with marked splenomegaly and neutropenia in the setting of rheumatoid arthritis - Felty syndrome and hepatosplenic T cell lymphoma mask, Am J Blood Res, 11, 227 Kucuk, 2015, Activating mutations of STAT5B and STAT3 in lymphomas derived from gammadelta-T or NK cells, Nat Commun, 6, 6025, 10.1038/ncomms7025 Fan, 2023, Indolent T-cell lymphoproliferative disorder of gastrointestinal tract with unusual clinical courses: report of 6 cases and literature review, Virchows Arch, 482, 729, 10.1007/s00428-022-03467-5 Sharma, 2018, Recurrent STAT3-JAK2 fusions in indolent T-cell lymphoproliferative disorder of the gastrointestinal tract, Blood, 131, 2262, 10.1182/blood-2018-01-830968 Hu, 2020, Targetability of STAT3-JAK2 fusions: implications for T-cell lymphoproliferative disorders of the gastrointestinal tract, Leukemia, 34, 1467, 10.1038/s41375-019-0678-3 Soderquist, 2020, Genetic and phenotypic characterization of indolent T-cell lymphoproliferative disorders of the gastrointestinal tract, Haematologica, 105, 1895, 10.3324/haematol.2019.230961 Ko, 2010, Enteropathy-associated T-cell lymphoma–a clinicopathologic and array comparative genomic hybridization study, Hum Pathol, 41, 1231, 10.1016/j.humpath.2009.11.020 Zettl, 2002, Chromosomal gains at 9q characterize enteropathy-type T-cell lymphoma, Am J Pathol, 161, 1635, 10.1016/S0002-9440(10)64441-0 Deleeuw, 2007, Whole-genome analysis and HLA genotyping of enteropathy-type T-cell lymphoma reveals 2 distinct lymphoma subtypes, Gastroenterology, 132, 1902, 10.1053/j.gastro.2007.03.036 Moffitt, 2017, Enteropathy-associated T cell lymphoma subtypes are characterized by loss of function of SETD2, J Exp Med, 214, 1371, 10.1084/jem.20160894 Obermann, 2004, Loss of heterozygosity at chromosome 9p21 is a frequent finding in enteropathy-type T-cell lymphoma, J Pathol, 202, 252, 10.1002/path.1506 Malamut, 2009, Presentation and long-term follow-up of refractory celiac disease: comparison of type I with type II, Gastroenterology, 136, 81, 10.1053/j.gastro.2008.09.069 Soderquist, 2021, Immunophenotypic spectrum and genomic landscape of refractory celiac disease type II, Am J Surg Pathol, 45, 905, 10.1097/PAS.0000000000001658 Nicolae, 2016, Mutations in the JAK/STAT and RAS signaling pathways are common in intestinal T-cell lymphomas, Leukemia, 30, 2245, 10.1038/leu.2016.178 Tomita, 2015, Genomic and immunohistochemical profiles of enteropathy-associated T-cell lymphoma in Japan, Mod Pathol, 28, 1286, 10.1038/modpathol.2015.85 Chen, 2021, Clinicopathological and molecular genomic features of monomorphic epitheliotropic intestinal T-cell lymphoma in the Chinese population: a study of 20 cases, Diagn Pathol, 16, 114, 10.1186/s13000-021-01173-5 Kikuma, 2014, Detailed clinicopathological characteristics and possible lymphomagenesis of type II intestinal enteropathy-associated T-cell lymphoma in Japan, Hum Pathol, 45, 1276, 10.1016/j.humpath.2013.10.038 Veloza, 2023, Monomorphic epitheliotropic intestinal T-cell lymphoma comprises morphologic and genomic heterogeneity impacting outcome, Haematologica, 108, 181, 10.3324/haematol.2022.281226 Okumura, 2012, An unusual enteropathy-associated T-cell lymphoma with MYC translocation arising in a Japanese patient: a case report, World J Gastroenterol, 18, 2434, 10.3748/wjg.v18.i19.2434 Tan, 2013, Type II EATL (epitheliotropic intestinal T-cell lymphoma): a neoplasm of intra-epithelial T-cells with predominant CD8alphaalpha phenotype, Leukemia, 27, 1688, 10.1038/leu.2013.41 Vaira, 2020, Deregulation of miRNAs-cMYC circuits is a key event in refractory celiac disease type-2 lymphomagenesis, Clin Sci (Lond), 134, 1151, 10.1042/CS20200032 Roberti, 2016, Type II enteropathy-associated T-cell lymphoma features a unique genomic profile with highly recurrent SETD2 alterations, Nat Commun, 7, 12602, 10.1038/ncomms12602 Wong, 1999, Cytogenetic abnormalities in natural killer cell lymphoma/leukaemia–is there a consistent pattern?, Leuk Lymphoma, 34, 241, 10.3109/10428199909050949 Yang, 2018, Aggressive natural killer (NK)-cell leukaemia and extranodal NK/T-cell lymphoma are two distinct diseases that differ in their clinical presentation and cytogenetic findings, Histopathology, 72, 955, 10.1111/his.13463 Dong, 2022, Genomic profiling identifies distinct genetic subtypes in extra-nodal natural killer/T-cell lymphoma, Leukemia, 36, 2064, 10.1038/s41375-022-01623-z Xiong, 2020, Genomic and transcriptomic characterization of natural killer T cell lymphoma, Cancer Cell, 37, 10.1016/j.ccell.2020.02.005 D'Costa, 2003, Phytohemagglutinin inhibits lymphoid tumor growth in vitro and in vivo, Leuk Lymphoma, 44, 1785, 10.1080/1042819031000119217 Shimodaira, 1995, The detection of clonal proliferation in granular lymphocyte-proliferative disorders of natural killer cell lineage, Br J Haematol, 90, 578, 10.1111/j.1365-2141.1995.tb05587.x Moskowitz, 2021, A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas, Blood, 138, 2828, 10.1182/blood.2021013379